Next 10 |
2024-07-05 12:07:45 ET More on Castle Biosciences Castle Biosciences, Inc. (CSTL) Q1 2024 Earnings Call Transcript Seeking Alpha’s Quant Rating on Castle Biosciences Historical earnings data for Castle Biosciences Financial information for Castle Biosc...
Castle’s TissueCypher test has been shown to improve the risk stratification of patients with Barrett’s esophagus (BE) 1,2 Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the lat...
Maetzold selected as a winner of Ernst & Young’s prestigious annual awards among 48 visionary finalists in the Gulf South region, encompassing Central and South Texas, Louisiana and Mississippi Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innova...
Castle to present a second poster on its DecisionDx®-UM test sharing data from an ongoing prospective, multi-center study of patients with uveal melanoma (UM) led by the Collaborative Ocular Oncology Group (COOG2) Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health ...
2024-05-30 02:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
In the study, patients with DecisionDx-SCC Class 2B test results, predicted to have the highest risk of metastasis by the test, who were treated with adjuvant radiation therapy (ART) had 50% higher metastasis-free survival (MFS) rates, on average, and slowed disease progression compared to Class ...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024, at 2:...
In collaboration with leading GI experts, Castle has also planned several educational sessions at DDW 2024, including a product theater and two American Society for Gastrointestinal Endoscopy (ASGE) theater talks Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health throug...
This marks the fourth consecutive year that Castle has earned a MedTech Breakthrough Award for its innovative testing solutions Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been selected...
Oral presentation at ARVO shares ground-breaking findings from the ongoing Collaborative Ocular Oncology Group (COOG) study 2 (COOG2) of patients with uveal melanoma (UM) Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
4.03%Change Percent:
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NYSE Market:
Castle Biosciences Inc. Website:
Castle’s TissueCypher test has been shown to improve the risk stratification of patients with Barrett’s esophagus (BE) 1,2 Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the lat...
Maetzold selected as a winner of Ernst & Young’s prestigious annual awards among 48 visionary finalists in the Gulf South region, encompassing Central and South Texas, Louisiana and Mississippi Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innova...
Castle to present a second poster on its DecisionDx®-UM test sharing data from an ongoing prospective, multi-center study of patients with uveal melanoma (UM) led by the Collaborative Ocular Oncology Group (COOG2) Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health ...